Hardman & Co Research · ISIN: GB00BYV81293 · EQS - Company News

Shield Therapeutics (STX) Investor Forum

Hardman & Co Video Event | Shield Therapeutics (STX) Investor Forum We are delighted to announce that Shield Therapeutics (STX) will be presenting at Hardman & Co's upcoming Investor Forum at 3:00pm this Thursday 14 November 2024. Register for the event to secure your place and submit questions. A commercial-stage pharmaceutical company, Shield Therapeutics is strategically positioned to address the significant unmet medical needs of patients suffering from iron deficiency. Since laun...

FWB:1JS Price indication powered by TradingView

About the publication

Corporate Insights - Short Sales, Director's Dealings, Sentiment Indicators - THE info hub for the informed investor

Smart tools for smart investors can be found in our Tools section

Corporate News Hardman & Co Research

In this overview you can view company news in the chronological order of publication. The source information comes from EQS News, the leading European news distributor. The most recent news item is listed first.
Back to Corporate News Overview
This might be interesting for you as well
Analyst Ratings (0)
Directors Dealings (0)
Short Selling (DE) (0)
Short Selling (UK) (0)
11 November 2024 03:00PM
Shield Therapeutics (STX) Investor Forum
GB00BYV81293
Hardman & Co Video Event | Shield Therapeutics (STX) Investor Forum We are delighted to announce that Shield Therapeutics (STX) will be presenting at Hardman & Co's upcoming Investor Forum at 3:00pm this Thursday 14 November 2024. Register for the event to secure your place and submit questions. A commercial-stage pharmaceutical company,...
Hardman & Co Research
About the publication
11 September 2024 01:25PM
Focusing on successful execution
GB00BYV81293
Hardman & Co Research on Shield Therapeutics (STX): Focusing on successful execution   Shield is a commercial-stage pharma company delivering specialty products that address the unmet medical need of patients with iron deficiency (ID). Since its July 2021 US launch, Shield and Viatris have increased physician awareness of the differentiating...
Hardman & Co Research
About the publication
23 May 2024 08:15AM
Cash management is key
GB00BYV81293
Hardman & Co Research on Shield Therapeutics (STX): Cash management is key   Shield is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID). Since its US launch in July 2021, Shield and its partner, Viatris, have increased physician awareness...
Hardman & Co Research
About the publication
15 November 2023 08:30AM
Accelerating effectiveness of enlarged sales team
GB00BYV81293
Hardman & Co Research on Shield Therapeutics (STX): Accelerating effectiveness of enlarged sales team   Shield is a commercial-stage pharma company delivering specialty products that address patients’ unmet medical needs, with an initial focus on iron deficiency (ID). Since its US launch in July 2021, Shield has been increasing physician awa...
Hardman & Co Research
About the publication
More Hardman & Co Research related information
Type Total Last Made by Go to
Corporate Research 0 - - Corporate Research
Directors Dealings 0 - - DD
Short Seller (DE) 0 - - SSR (DE)
Short Seller (UK) 0 - - SSR (UK)
Disclaimer:

The combination of information with graphic elements makes an important contribution to visual orientation and navigation through complex factual topics. Essential content features can be perceived, grasped and contextually processed much faster. 
The figurative marks, logos and other graphic and textual elements used on this website are for illustrative purposes only. All rights to the aforementioned elements are held by their respective owners. They are used without the intention of copyright infringement or intellectual property infringement.

If you believe that copyrights or intellectual property have been infringed by the choice of illustration, please contact us immediately to clarify the issue.

v.07062023 EN